Endocare completes Timm sale to UK's Plethora solutions:
This article was originally published in Clinica
Endocare has closed the sale of its erectile dysfunction subsidiary, Timm Medical Technologies, to UK company Plethora Solutions. London-based Plethora, which develops drugs and devices for the urology market, agreed in January to pay Endocare $9.5m in cash and bonds for Timm (see Clinica No 1190, p 14).
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.